

Important Contact Information

If you have questions about our P4P Programs, please contact your Provider Engagement Account Manager or Provider Relations at: PHWProviderRelations@PAHealthWellness.com

2026 PA Health & Wellness Community HealthChoices Pay for Performance



PA Health & Wellness (PHW) exists to improve the health of its Participants through focused, compassionate, and coordinated care. Our approach is based on the core belief that quality healthcare is best delivered locally. PHW understands that the Provider-Patient relationship is a key component in ensuring superior healthcare and the satisfaction of our Community HealthChoices (CHC) Participants. Because PHW recognizes these important partnerships, we are pleased to offer the 2026 Pay for Performance (P4P) Incentive Program, which rewards PCPs for improving quality and closing gaps in care.

The 2026 P4P Program consists of 8 HEDIS® measures. Providers in the P4P Program can earn incentives at 2 levels based upon the established benchmarks for each measure. Target performance is determined by comparing a P4P provider's compliance percentage for a given program measure to the established benchmarks. Each measure will be calculated and rewarded individually. Bonuses are calculated and paid out to the eligible Participant's provider of record at the end of the applicable measurement periods as defined by the P4P Program.

PA Health & Wellness P4P Provider Performance Scorecard 2026 P4P Measures	Target 1 50th % Quality Compass	Target 1 Bonus 50% Incentive	Target 2 75th % Quality Compass	Target 2 Bonus 100% Incentive
BCS - Breast Cancer Screening	58.93%	\$75	66.31%	\$150
BPD - Diabetes BP < 140/90	74.21%	\$150	78.83%	\$300
CBP - Controlling High Blood Pressure	70.35%	\$150	75.43%	\$300
CCS - Cervical Cancer Screening	55.86%	\$75	64.21%	\$150
COL - Colorectal Cancer Screen (46 - 75 Yrs)	45.84%	\$75	53.31%	\$150
EED - Diabetes - Dilated Eye Exam	60.83%	\$75	68.61%	\$150
GSD - Diabetes HbA1c < 8	63.04%	\$150	67.40%	\$300
KED - Kidney Health for Patients with Diabetes	46.17%	\$150	54.15%	\$300

New to P4P this year: Cervical Cancer Screening (CCS) — **Targets:** When Target 1 Quality Compass percentage of the member panel is reached, 50% of the total incentive bonus will be paid for members closing gaps above the Target 1 level. When Target 2 Quality Compass percentage of the member panel is reached, the remaining 50% of the incentive bonus will be paid for members closing gaps above the Target 2 Level, totaling 100% of the potential incentive bonus.

BCS-E - Breast Cancer Screening

Female Patients 50-74 years of age

Mammogram – every 2 years

77061-77063, 77065-77067, 1208601007, 836381000000102,
1106021000000101, 1106641000000102, 1106651000000104,
1106661000000101, 1111381000000105, 1111411000000107,
1111421000000101, 1111791000000108

BPD - Blood Pressure Control for Patients with Diabetes

Patients 18-75 years of age

Most recent BP in MY

Compliant BP = Less than 140/90

3074F: SBP <140, 3075F: SBP 130-139
3077F: SBP equal to or > 140
3078F: DBP < 80, 3079F : DBP 80-90
3080F: DBP equal to or > 90

Continued
on back...

CBP - Controlling High Blood Pressure

Patients 18-75 years of age

Most recent BP in MY
Compliant BP = Less than 140/90

3074F: SBP <140, 3075F: SBP 130-139
3077F: SBP equal to or > 140
3078F: DBP < 80, 3079F : DBP 80–90
3080F: DBP equal to or > 90

CCS - Cervical Cancer Screening

Female Patients 21–64 years of age who were recommended for routine cervical cancer screening.

Females who were recommended for routine cervical cancer screening and...

- are 21–64 years of age and had cervical cytology performed within the last 3 years.
- are 30–64 years of age and had cervical high-risk humanpapillomavirus (hrHPV) testing performed within the last 5 years.
- are 30–64 years of age and had cervical cytology / high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

Cervical Cytology Lab Test (20-64)

CPT: 88141-88143, 88147, 88148, 88150, 88152-88153, 88164-88167, 88174, 88175

HCPCS: G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091

HPV Tests (30-64)

CPT: 87624, 87625

HCPCS: G0476

Hysterectomy with No Residual Cervix and Absence of Cervix Diagnosis

CPT: 57530, 57531, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550, 58552-58554, 58570-58573, 58575, 58951, 58953, 58954, 58956, 59135

ICD-10: Q51.5, Z90.710, Z90.712

SNOMED: 1163275000

Palliative Care

HCPCS: G9054, M1017

COL - Colorectal Cancer Screening

Patients 45-75 years of age who had appropriate screening for colorectal cancer screening.

Potential screening methods include an annual Guaiac-based Fecal Occult Blood Test),
or Fecal Immunochemical Test (FIT),
or Multitargeted Stool DNA with FIT test every 3 years,
or Colonoscopy every 10 years,
or CT Colonography every 5 years,
or Flexible Sigmoidoscopy every 5 years

– Colonoscopy 2.16.840.1.113883.3.464.1004.1064
– CT Colonography 2.16.840.1.113883.3.464.1004.1421
– Flexible Sigmoidoscopy 2.16.840.1.113883.3.464.1004.1102
– FOBT Lab Test 2.16.840.1.113883.3.464.1004.1959)
– FOBT Test Result or Finding 2.16.840.1.113883.3.464.1004.1960
– sDNA FIT Lab Test 2.16.840.1.113883.3.464.1004.1749
– Total Colectomy 2.16.840.1.113883.3.464.1004.1250
– Colorectal Cancer 2.16.840.1.113883.3.464.1004.1065

EED - Eye Exam for Patients with Diabetes

Patients 18-75 years of age

Dilated Retinal Eye Exam (DRE) – Yearly

Negative Screen: 2023F, 2026F
Positive Screen: 2022F, 2024F
Negative Screen Prior Year: 3072F
Automated Eye Exam: 92229, S0620, S0621, S3000
Diabetic Retinal Screening S0620, S0621, S3000

GSD - Glycemic Status Assessment for Patients with Diabetes

Patients 18-75 years of age

Members with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year.

- Glycemic Status <8.0%.
- Glycemic Status >9.0%.

3044F: < 7.0
3051F: 7 – 7.9
3052F: 8 – 9
3046F: >9

KED - Kidney Health Evaluation for Patients with Diabetes

Patients 18-85 years of age

Estimated glomerular filtration rate (eGFR)
AND
Urine albumin - creatinine ratio (uACR) yearly

eGFR: 80047, 80048, 80050, 80053, 80069, 82565
Urine Quantitative Albumin Test: 82043
Urine Creatinine Test: 82570